- Home
- DAWN vs OLMA Comparison
DAWN vs OLMA Comparison
Compare DAWN & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- OLMA
- Stock Information
- Founded
- DAWN 2018
- OLMA 2006
- Country
- DAWN United States
- OLMA United States
- Employees
- DAWN N/A
- OLMA N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- DAWN Health Care
- OLMA Health Care
- Exchange
- DAWN Nasdaq
- OLMA Nasdaq
- Market Cap
- DAWN 1.3B
- OLMA 465.4M
- IPO Year
- DAWN 2021
- OLMA 2020
- Fundamental
- Price
- DAWN $12.79
- OLMA $6.10
- Analyst Decision
- DAWN Strong Buy
- OLMA Strong Buy
- Analyst Count
- DAWN 7
- OLMA 5
- Target Price
- DAWN $36.17
- OLMA $26.25
- AVG Volume (30 Days)
- DAWN 1.0M
- OLMA 1.2M
- Earning Date
- DAWN 10-30-2024
- OLMA 11-12-2024
- Dividend Yield
- DAWN N/A
- OLMA N/A
- EPS Growth
- DAWN N/A
- OLMA N/A
- EPS
- DAWN N/A
- OLMA N/A
- Revenue
- DAWN $101,953,000.00
- OLMA N/A
- Revenue This Year
- DAWN N/A
- OLMA N/A
- Revenue Next Year
- DAWN $36.10
- OLMA N/A
- P/E Ratio
- DAWN N/A
- OLMA N/A
- Revenue Growth
- DAWN N/A
- OLMA N/A
- 52 Week Low
- DAWN $11.94
- OLMA $5.56
- 52 Week High
- DAWN $18.07
- OLMA $16.78
- Technical
- Relative Strength Index (RSI)
- DAWN 39.97
- OLMA 27.05
- Support Level
- DAWN $12.26
- OLMA $5.56
- Resistance Level
- DAWN $12.81
- OLMA $6.87
- Average True Range (ATR)
- DAWN 0.52
- OLMA 0.81
- MACD
- DAWN -0.05
- OLMA -0.28
- Stochastic Oscillator
- DAWN 28.94
- OLMA 10.12
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.